AbCellera (Group)

https://www.abcellera.com

AbCellera is a privately held company that engages in partnerships to discover and develop next-generation therapeutic antibodies. AbCellera’s single-cell platform integrates end-to-end capabilities for therapeutic antibody discovery through a combination of technologies including proprietary immunizations, microfluidics, high-throughput imaging, genomics, computation, and laboratory automation. Ultra-deep screening of single B cells allows unprecedented access to natural immune responses, enabling rapid isolation of large and diverse panels of high-quality lead antibodies from any species, including humans. *

	Start	2012-01-01 established
	Predecessor	University of British Columbia (UBC)
	Industry	MAb
	Industry 2	single cell analysis
	Person	Hansen, Carl (AbCellera 201902 CEO)

	Region	Vancouver, BC
	Country	Canada
	Street	2215 Yukon Street
	City	V5Y 0A1 Vancouver, BC
	Tel	+1-604-559-9005
		Address record changed: 2024-01-05

Basic data	Employees	B: 11 to 50 (2017-10-13)

		* Document for »About Section«: AbCellera Biologics, Inc.. (2/14/19). "Press Release: AbCellera Announces Multi-Target Partnership Agreement with a Top 5 Global Pharma". Vancouver, BC.

		Record changed: 2023-07-10

Picture Berlin Partner Events Bionnale 2025 May HealthCapital 650x200px

More documents for AbCellera (Group)

[1] AbCellera Biologics, Inc.. (2/14/19). "Press Release: AbCellera Announces Multi-Target Partnership Agreement with a Top 5 Global Pharma". Vancouver, BC....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]